{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:55Z","timestamp":1777876855364,"version":"3.51.4"},"reference-count":58,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p>Cutaneous adverse reactions are reported for many therapeutic agents and, in general, are observed in between 0% and 8% of treated patients depending on the drug. Antiosteoporotic agents are considered to be safe in terms of cutaneous effects, however there have been a number of case reports of cutaneous adverse reactions which warrant consideration. This was the subject of a working group meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis in April 2009, which focused on the impact of cutaneous adverse reactions and drug-induced hypersensitivity in the management of postmenopausal osteoporosis. This position paper was drafted following these discussions and includes a flowchart for their recognition. Cutaneous adverse reactions observed with antiosteoporotic agents were reviewed and included information from case reports, regulatory documents and pharmacovigilance. These reactions ranged from benign effects including exanthematous or maculopapular eruption (drug rash), photosensitivity and urticaria, to the severe and potentially life-threatening reactions of angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens Johnson syndrome and toxic epidermal necrolysis. A review of the available evidence demonstrates that cutaneous adverse reactions occur with all commonly used antiosteoporotic treatments. Notably, there are reports of Stevens Johnson syndrome and toxic epidermal necrolysis for bisphosphonates, and of DRESS and toxic epidermal necrolysis for strontium ranelate. These severe reactions remain very rare (&lt;1 in 10,000 cases). In general, with proper management and early recognition, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization, rehydration and systemic corticosteroids if necessary, the prognosis is positive.<\/jats:p>","DOI":"10.1177\/1759720x10387202","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T20:35:32Z","timestamp":1289507732000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cutaneous Side Effects of Antiosteoporosis Treatments"],"prefix":"10.1177","volume":"3","author":[{"given":"Philippe","family":"Musette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gent University Hospital, B-9000 Gent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Geriatrix \u2014 Service of Bone Diseases, Geneva University Hospital, 1211 Geneva 14, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re and Universit\u00e9 Pierre et Marie Curie, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Louisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"bibr1-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmec.2008.09.009"},{"key":"bibr2-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1159\/000104206"},{"key":"bibr3-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070102"},{"key":"bibr4-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1986-1"},{"key":"bibr5-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01836.x"},{"key":"bibr6-1759720X10387202","first-page":"765","volume":"137","author":"Bigby M.","year":"2001","journal-title":"Arch Dermatol"},{"key":"bibr7-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1399-y"},{"key":"bibr8-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.50"},{"key":"bibr9-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02856.x"},{"key":"bibr10-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(96)80038-1"},{"key":"bibr11-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.06.004"},{"key":"bibr12-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2006.01071.x"},{"key":"bibr13-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0981"},{"key":"bibr14-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09075-8"},{"key":"bibr15-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(94)90813-3"},{"key":"bibr16-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"bibr17-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116756"},{"key":"bibr18-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"bibr19-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.145.1.67"},{"key":"bibr20-1759720X10387202","volume-title":"Ibandronate. Summary of Product Characteristics","author":"EMA","year":"2007"},{"key":"bibr21-1759720X10387202","volume-title":"Parathyroid Hormone. Summary of Product Characteristics","author":"EMA","year":"2007"},{"key":"bibr22-1759720X10387202","volume-title":"Alendronate. Summary of Product Characteristics","author":"EMA","year":"2008"},{"key":"bibr23-1759720X10387202","volume-title":"Zoledronic Acid. Summary of Product Characteristics","author":"EMA","year":"2008"},{"key":"bibr24-1759720X10387202","volume-title":"Strontium Ranelate. Summary of Product Characteristics","author":"EMA","year":"2008"},{"key":"bibr25-1759720X10387202","volume-title":"Raloxifene. Summary of Product Characteristics","author":"EMA","year":"2008"},{"key":"bibr26-1759720X10387202","volume-title":"Teriparatide. Summary of Product Characteristics","author":"EMA","year":"2008"},{"key":"bibr27-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565150-00002"},{"key":"bibr28-1759720X10387202","volume-title":"Risedronate. Description","author":"FDA","year":"2002"},{"key":"bibr29-1759720X10387202","volume-title":"Pharmapendium","author":"FDA","year":"2009"},{"key":"bibr30-1759720X10387202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","volume":"8","author":"Ghislain P.D.","year":"2002","journal-title":"Dermatol Online J"},{"key":"bibr31-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1097\/01.all.0000173785.81024.33"},{"key":"bibr32-1759720X10387202","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2008.03273.x","volume":"66","author":"Grosso A.","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"bibr33-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2007.54"},{"key":"bibr34-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.245"},{"key":"bibr35-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"bibr36-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb01017.x"},{"key":"bibr37-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.01940.x"},{"key":"bibr38-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2003.480212_2.x"},{"key":"bibr39-1759720X10387202","first-page":"398","volume":"80","author":"Kontoleon P.","year":"2000","journal-title":"Ada Derm Venereol"},{"key":"bibr40-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1710-6"},{"key":"bibr41-1759720X10387202","first-page":"389","volume":"4","author":"Lazarov A.","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"bibr42-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0677-0"},{"key":"bibr43-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706135"},{"key":"bibr44-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459"},{"key":"bibr45-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1159\/000104186"},{"key":"bibr46-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"bibr47-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp022558"},{"key":"bibr48-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0734-8"},{"key":"bibr49-1759720X10387202","first-page":"455","volume":"24","author":"Rizos E.C.","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"bibr50-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.022"},{"key":"bibr51-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.268"},{"key":"bibr52-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.55.1"},{"key":"bibr53-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1159\/000104205"},{"key":"bibr54-1759720X10387202","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0031-6997(24)01501-1","volume":"53","author":"Svensson C.K.","year":"2001","journal-title":"Pharmacol Rev"},{"key":"bibr55-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730110-00003"},{"key":"bibr56-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5388.490"},{"key":"bibr57-1759720X10387202","volume-title":"Le Dictionnaire, 85th edn, Issy-les-Moulineaux","author":"Vidal L.","year":"2009"},{"key":"bibr58-1759720X10387202","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.06.012"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X10387202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X10387202","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X10387202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:34:44Z","timestamp":1777588484000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X10387202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1177\/1759720X10387202"],"URL":"https:\/\/doi.org\/10.1177\/1759720x10387202","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}